{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.7","upperLimit":"20.5","value":"11.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"55"}],"units":"Participants"}],"description":"RFS: time from brexucabtagene autoleucel infusion to date of disease relapse or death from any cause. Participants not meeting criteria for relapse by the analysis data cutoff date were censored at their last evaluable disease assessment date. Participants who had not achieved a CR or CRi at analysis data cutoff were evaluated as an RFS event at Day 0. CR and CRi are defined in Outcome Measures 4 and 5. Relapse is defined in Outcome Measure 6. KM estimates was used for analyses.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with r/r B-ALL received conditioning chemotherapy (fludarabine 25 mg/m\\^2 IV over 30 minutes on Day -4, Day -3, and Day -2 and cyclophosphamide 900 mg/m\\^2 IV over 60 minutes on Day -2) followed by a single infusion of brexucabtagene autoleucel CAR transduced autologous T cells administered IV at a target dose of 1 x 10\\^6 anti-CD19 CAR T cells/kg of body weight on Day 0. For participants weighing \\> 100 kg, a maximum flat dose of 1 x 10\\^8 anti-CD19 CAR T cells/kg of body weight was administered.","id":"OG000","title":"Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg"}],"paramType":"MEDIAN","populationDescription":"Participants in mITT Analysis Set were analyzed.","reportingStatus":"POSTED","timeFrame":"First infusion date of brexucabtagene autoleucel (Phase 2) up to 3.7 years","title":"Phase 2: Relapse-free Survival (RFS)","type":"SECONDARY","unitOfMeasure":"months"}